Boston Scientific elected Donna A. James to its board of directors. Ms. James is the founder and managing director of Lardon & Associates, a business development and executive advisory services firm.
Twenty-five brokerage firms have given Boston Scientific an average rating of “buy” and an average price target of $18.55, according to a Dakota Financial News report.
Four analysts that cover EndoChoice stock have rated the company shares as a “strong buy,” according to a WKRB News & Analysis report. The company stock has a one-year consensus price target of $23.33.
Ferring Pharmaceuticals and Intralytix formed a new partnership geared toward developing bacteriophage-based drugs designed to treat inflammatory bowel disease.
gMed, a GI practice and ASC EHR company, held its annual summit meeting in Ft. Lauderdale, Fla., from June 18 to June 20.
If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.
More articles on gastroenterology:
CMS proposes colonoscopy payment cuts for 2016: 4 key points
3 GI physicians in the news – July 10, 2015
Looking back: Memorable moments in GI
